Portal de Periódicos da CAPES

Overview of Phase I Trials of 2′,3′-Dideoxyinosine (ddI) Conducted on Adult Patients

1990; Oxford University Press; Volume: 12; Issue: Supplement_5 Linguagem: Inglês

10.1093/clinids/12.supplement_5.s570

1537-6591

Marcel Rozencweig, C. McLaren, Mohan Beltangady, Jitka K. Ritter, Renzo Canetta, Lee Schacter, Susan L. Kelley, Claude Nicaise, Laurie Smaldone, Lisa M. Dunkle, Rashmi H. Barbhaiya, C A Knupp, Anne Cross, MICHAEL C. TSIANCO, R. Russell Martin,

HIV-related health complications and treatments

Journal Article Overview of Phase I Trials of 2′,3′-Dideoxyinosine (ddI) Conducted on Adult Patients Get access Marcel Rozencweig, Marcel Rozencweig Pharmaceutical Research and Development Division, Bristol-Myers Squibb Company, Departments of Cancer Clinical Research, Infectious Diseases, and Biostatistics and Data Management, Wallingford, Connecticut; and Department of Metabolism and Pharmacokinetics, Syracuse, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar Colin McLaren, Colin McLaren Pharmaceutical Research and Development Division, Bristol-Myers Squibb Company, Departments of Cancer Clinical Research, Infectious Diseases, and Biostatistics and Data Management, Wallingford, Connecticut; and Department of Metabolism and Pharmacokinetics, Syracuse, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar Mohan Beltangady, Mohan Beltangady Pharmaceutical Research and Development Division, Bristol-Myers Squibb Company, Departments of Cancer Clinical Research, Infectious Diseases, and Biostatistics and Data Management, Wallingford, Connecticut; and Department of Metabolism and Pharmacokinetics, Syracuse, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar Jitka Ritter, Jitka Ritter Pharmaceutical Research and Development Division, Bristol-Myers Squibb Company, Departments of Cancer Clinical Research, Infectious Diseases, and Biostatistics and Data Management, Wallingford, Connecticut; and Department of Metabolism and Pharmacokinetics, Syracuse, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar Renzo Canetta, Renzo Canetta Pharmaceutical Research and Development Division, Bristol-Myers Squibb Company, Departments of Cancer Clinical Research, Infectious Diseases, and Biostatistics and Data Management, Wallingford, Connecticut; and Department of Metabolism and Pharmacokinetics, Syracuse, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar Lee Schacter, Lee Schacter Pharmaceutical Research and Development Division, Bristol-Myers Squibb Company, Departments of Cancer Clinical Research, Infectious Diseases, and Biostatistics and Data Management, Wallingford, Connecticut; and Department of Metabolism and Pharmacokinetics, Syracuse, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar Susan Kelley, Susan Kelley Pharmaceutical Research and Development Division, Bristol-Myers Squibb Company, Departments of Cancer Clinical Research, Infectious Diseases, and Biostatistics and Data Management, Wallingford, Connecticut; and Department of Metabolism and Pharmacokinetics, Syracuse, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar Claude Nicaise, Claude Nicaise Pharmaceutical Research and Development Division, Bristol-Myers Squibb Company, Departments of Cancer Clinical Research, Infectious Diseases, and Biostatistics and Data Management, Wallingford, Connecticut; and Department of Metabolism and Pharmacokinetics, Syracuse, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar Laurie Smaldone, Laurie Smaldone Pharmaceutical Research and Development Division, Bristol-Myers Squibb Company, Departments of Cancer Clinical Research, Infectious Diseases, and Biostatistics and Data Management, Wallingford, Connecticut; and Department of Metabolism and Pharmacokinetics, Syracuse, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar Lisa Dunkle, Lisa Dunkle Pharmaceutical Research and Development Division, Bristol-Myers Squibb Company, Departments of Cancer Clinical Research, Infectious Diseases, and Biostatistics and Data Management, Wallingford, Connecticut; and Department of Metabolism and Pharmacokinetics, Syracuse, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar ... Show more Rashmi Barbhaiya, Rashmi Barbhaiya Pharmaceutical Research and Development Division, Bristol-Myers Squibb Company, Departments of Cancer Clinical Research, Infectious Diseases, and Biostatistics and Data Management, Wallingford, Connecticut; and Department of Metabolism and Pharmacokinetics, Syracuse, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar Cathy Knupp, Cathy Knupp Pharmaceutical Research and Development Division, Bristol-Myers Squibb Company, Departments of Cancer Clinical Research, Infectious Diseases, and Biostatistics and Data Management, Wallingford, Connecticut; and Department of Metabolism and Pharmacokinetics, Syracuse, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar Anne Cross, Anne Cross Pharmaceutical Research and Development Division, Bristol-Myers Squibb Company, Departments of Cancer Clinical Research, Infectious Diseases, and Biostatistics and Data Management, Wallingford, Connecticut; and Department of Metabolism and Pharmacokinetics, Syracuse, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael Tsianco, Michael Tsianco Pharmaceutical Research and Development Division, Bristol-Myers Squibb Company, Departments of Cancer Clinical Research, Infectious Diseases, and Biostatistics and Data Management, Wallingford, Connecticut; and Department of Metabolism and Pharmacokinetics, Syracuse, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar R. Russell Martin R. Russell Martin Pharmaceutical Research and Development Division, Bristol-Myers Squibb Company, Departments of Cancer Clinical Research, Infectious Diseases, and Biostatistics and Data Management, Wallingford, Connecticut; and Department of Metabolism and Pharmacokinetics, Syracuse, New York Please address requests for reprints to Dr. R. Russell Martin, Bristol-Myers Squibb Company, Pharmaceutical Research and Development Division, 5 Research Parkway (P.O.Box 5100-Dept. 102), Wallingford, Connecticut 06492-7660. Search for other works by this author on: Oxford Academic PubMed Google Scholar Reviews of Infectious Diseases, Volume 12, Issue Supplement_5, July-August 1990, Pages S570–S575, https://doi.org/10.1093/clinids/12.Supplement_5.S570 Published: 01 July 1990